Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 32


Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Doubeni CA, Epling JW Jr, Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Simon MA, Tseng CW, Wong JB.

JAMA. 2019 Aug 20;322(7):652-665. doi: 10.1001/jama.2019.10987.


Association of mRNA expression levels of Cullin family members with prognosis in breast cancer: An online database analysis.

Liu A, Zhang S, Shen Y, Lei R, Wang Y.

Medicine (Baltimore). 2019 Aug;98(31):e16625. doi: 10.1097/MD.0000000000016625.


Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.

Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr.

N Engl J Med. 2019 Jun 20;380(25):2395-2405. doi: 10.1056/NEJMoa1904819. Epub 2019 Jun 3.


Practical application of non-contact alternating current electric field mixing for reagent-saving in situ hybridisation of HER2.

Kurihara N, Imai K, Nanjo H, Nakamura R, Wakamatsu Y, Akagami K, Terata K, Wakita A, Sato Y, Motoyama S, Akagami Y, Minamiya Y.

J Clin Pathol. 2019 Sep;72(9):603-608. doi: 10.1136/jclinpath-2019-205830. Epub 2019 May 25.


Associations between XRCC3 Thr241Met polymorphisms and breast cancer risk: systematic-review and meta-analysis of 55 case-control studies.

Dashti S, Taherian-Esfahani Z, Keshtkar A, Ghafouri-Fard S.

BMC Med Genet. 2019 May 10;20(1):79. doi: 10.1186/s12881-019-0809-8.


Prevalence of BRCA mutations among hereditary breast and/or ovarian cancer patients in Arab countries: systematic review and meta-analysis.

Abdulrashid K, AlHussaini N, Ahmed W, Thalib L.

BMC Cancer. 2019 Mar 21;19(1):256. doi: 10.1186/s12885-019-5463-1.


Development of prognostic signature and nomogram for patients with breast cancer.

Su J, Miao LF, Ye XH, Cui MS, He XF.

Medicine (Baltimore). 2019 Mar;98(11):e14617. doi: 10.1097/MD.0000000000014617.


Nucleostemin expression in breast cancer is a marker of more aggressive phenotype and unfavorable patients' outcome: A STROBE-compliant article.

Sami MM, Hachim MY, Hachim IY, Elbarkouky AH, López-Ozuna VM.

Medicine (Baltimore). 2019 Mar;98(9):e14744. doi: 10.1097/MD.0000000000014744.


Molecular Drivers of Breast Implant-Associated Anaplastic Large Cell Lymphoma.

Blombery P, Thompson ER, Prince HM.

Plast Reconstr Surg. 2019 Mar;143(3S A Review of Breast Implant-Associated Anaplastic Large Cell Lymphoma):59S-64S. doi: 10.1097/PRS.0000000000005570. Review.


Is breast-conserving therapy adequate in BRCA 1/2 mutation carriers? The radiation oncologist's point of view.

Vallard A, Magné N, Guy JB, Espenel S, Rancoule C, Diao P, Deutsch E, Rivera S, Chargari C.

Br J Radiol. 2019 May;92(1097):20170657. doi: 10.1259/bjr.20170657. Epub 2019 Feb 27. Review.


A commentary on population genetic testing for primary prevention: changing landscape and the need to change paradigm.

Manchanda R, Gaba F.

BJOG. 2019 May;126(6):686-689. doi: 10.1111/1471-0528.15657.


Attitude towards and factors affecting uptake of population-based BRCA testing in the Ashkenazi Jewish population: a cohort study.

Manchanda R, Burnell M, Gaba F, Sanderson S, Loggenberg K, Gessler S, Wardle J, Side L, Desai R, Brady AF, Dorkins H, Wallis Y, Chapman C, Jacobs C, Tomlinson I, Beller U, Menon U, Jacobs I.

BJOG. 2019 May;126(6):784-794. doi: 10.1111/1471-0528.15654. Epub 2019 Mar 18.


Large-scale meta-analysis of mutations identified in panels of breast/ovarian cancer-related genes - Providing evidence of cancer predisposition genes.

Suszynska M, Klonowska K, Jasinska AJ, Kozlowski P.

Gynecol Oncol. 2019 May;153(2):452-462. doi: 10.1016/j.ygyno.2019.01.027. Epub 2019 Feb 4.


Weighted gene co-expression network analysis reveals modules and hub genes associated with the development of breast cancer.

Qiu J, Du Z, Wang Y, Zhou Y, Zhang Y, Xie Y, Lv Q.

Medicine (Baltimore). 2019 Feb;98(6):e14345. doi: 10.1097/MD.0000000000014345.


Combined effects of GSTM1 and GSTT1 polymorphisms on breast cancer risk: A MOOSE-compliant meta-analysis and false-positive report probabilities test.

Miao LF, Wang XY, Ye XH, Cui MS, He XF.

Medicine (Baltimore). 2019 Feb;98(6):e14333. doi: 10.1097/MD.0000000000014333.


Association of SENPs single-nucleotide polymorphism and breast cancer in Chinese population.

Cai J, Wei X, Zhang G, Sui Y, Zhuang J, Liu Z, Sun H.

Medicine (Baltimore). 2019 Feb;98(6):e14168. doi: 10.1097/MD.0000000000014168.


A Pilot Study Using a Multistaged Integrated Analysis of Gene Expression and Methylation to Evaluate Mechanisms for Evening Fatigue in Women Who Received Chemotherapy for Breast Cancer.

Flowers E, Flentje A, Levine J, Olshen A, Hammer M, Paul S, Conley Y, Miaskowski C, Kober KM.

Biol Res Nurs. 2019 Mar;21(2):142-156. doi: 10.1177/1099800418823286. Epub 2019 Jan 31.


Association of Interleukin-10 -1082A>G (rs1800896) Polymorphism with Predisposition to Breast Cancer: a Meta-Analysis based on 17 Case-Control Studies.

Abedinzadeh M, Neamatzadeh H, Jafari M, Forat-Yazdi M, Nasiri R, Farahnak S, Foroughi E, Zare-Shehneh M.

Rev Assoc Med Bras (1992). 2018 Aug;64(8):756-764. doi: 10.1590/1806-9282.64.08.756.

Supplemental Content

Loading ...
Support Center